Dr. Leslie A Andritsos, MD -Hematology and Oncology – Page 12

Dr. Leslie A Andritsos, MD -Hematology and Oncology

Registration: February 7, 2022

Comments: 0

Votes: 0

Total submitted: 224

About author

Dr. Leslie Ann Andritsos, MD, is a board‑certified hematologist and a Professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of New Mexico Comprehensive Cancer Center. She holds faculty appointments across Blood Disorders, Cancer Therapeutics, Medical Oncology, and the School of Medicine, reflecting her multidisciplinary expertise. UNM Health Sciences Center She is affiliated with University of New Mexico Hospitals and practices at multiple centers across Albuquerque, ensuring broad access to specialized hematology services. Dr. Andritsos earned her Doctor of Medicine degree from the University of Texas Medical Branch at Galveston in 1999. She completed her internship and residency training in Internal Medicine at Barnes‑Jewish Hospital in affiliation with Washington University School of Medicine from 1999 to 2001. She pursued fellowship training in Hematology/Oncology in 2004 and in Stem Cell Transplantation and Leukemia in 2005 at Barnes‑Jewish Hospital under Washington University School of Medicine. In her clinical role at UNM, Dr. Andritsos has dedicated over two decades to patient care, focusing on blood and marrow transplantation, cellular therapies, and the management of complex hematologic malignancies. She has led the development of post‑transplant modifications and quality‑of‑care initiatives that have significantly improved outcomes for patients with chronic lymphomas and leukemias. Her clinical interests extend to classical hematology, where she treats noncancerous blood disorders and myeloproliferative neoplasms, collaborating with dedicated pathologists, pharmacists, and coagulation specialists to deliver comprehensive care. Her practice integrates cutting‑edge research with compassionate, patient‑centered care to tailor treatment plans to individual patient needs. As a clinical investigator, her translational research has centered on chronic lymphocytic leukemia (CLL) and Hairy Cell Leukemia (HCL). Under her leadership, UNMCCC was named a Center of Excellence by the Hairy Cell Leukemia Foundation, and she chairs the foundation’s Scientific Review Committee for an international patient data registry. In this capacity, she collaborates with a multicenter, multidisciplinary team of scientists, clinicians, pathologists, and informatics specialists to refine diagnostic criteria, update risk stratification models, and assess quality‑of‑life outcomes for HCL patients. Her research collaborations have spanned multiple institutions, enabling large‑scale studies and accelerating the translation of laboratory discoveries into clinical protocols. Dr. Andritsos has authored over 287 peer‑reviewed publications with more than 8,000 citations, highlighting her prolific contributions to hematologic oncology research. Her achievements include the Maralyn S. Budke Endowed Professorship in Leukemia, Transplantation, and Cell‑Based Therapeutics. In 2016, she earned diplomate status with the American Board of Internal Medicine in Hematology. Beyond her clinical and research roles, Dr. Andritsos is committed to mentoring medical students, residents, and fellows, shaping the next generation of hematologists. She holds affiliations with University of New Mexico Hospitals and actively participates in institutional and national professional societies. Fluent in English, she collaborates seamlessly with multidisciplinary teams to advance patient care, education, and research in hematologic disorders. Committed to community outreach, she serves on advisory boards and presents at national and international forums to share insights on novel therapeutic approaches and quality‑of‑life interventions. Her leadership, collaborative spirit, and unwavering dedication to scientific discovery continue to drive innovations in hematology and oncology both at UNM and in the broader medical community.

User Posts: Dr. Leslie A Andritsos, MD -Hematology and Oncology

Moderate High ESR (41–80 mm/hr)

The erythrocyte sedimentation rate (ESR)—sometimes called the “sed rate”—measures how quickly red blood cells settle in a test tube over one hour. Normally, ...

Dr. Leslie A Andritsos, MD -Hematology and Oncology

READ MORE +

Mild High ESR (21–40 mm/hr)

The erythrocyte sedimentation rate (ESR) is a simple, cost‑effective blood test that measures how quickly red blood cells settle at the bottom of a vertical ...

Dr. Leslie A Andritsos, MD -Hematology and Oncology

READ MORE +

High Erythrocyte Sedimentation Rate (ESR) in Females

Erythrocyte sedimentation rate (ESR) is one of the oldest and simplest blood tests used to gauge inflammation in the body. In females, a persistently high ESR ...

Dr. Leslie A Andritsos, MD -Hematology and Oncology

READ MORE +

High ESR (Elevated Erythrocyte Sedimentation Rate)

An elevated erythrocyte sedimentation rate (ESR), often referred to as a “high sed rate,” is a common blood test finding that signals the presence of ...

Dr. Leslie A Andritsos, MD -Hematology and Oncology

READ MORE +

Browsing All Comments By: Dr. Leslie A Andritsos, MD -Hematology and Oncology

Moderate High ESR (41–80 mm/hr)

Mild High ESR (21–40 mm/hr)

High Erythrocyte Sedimentation Rate (ESR) in Females

High ESR (Elevated Erythrocyte Sedimentation Rate)

Mild High ESR (21–40 mm/hr)